Preferred Label : Eclutatug;
NCIt synonyms : Anti-claudin 1 Monoclonal Antibody ALE.C04; Anti-CLDN1 Monoclonal Antibody ALE.C04; Anti-claudin-1 Monoclonal Antibody ALE.C04;
NCIt definition : A humanized monoclonal antibody directed against the tumor-associated antigen (TAA)
claudin-1 (CLDN1; CLDN-1), with potential immunostimulating and antineoplastic activities.
Upon administration, eclutatug targets and binds to a specific extracellular loop
epitope that is exposed in non-junctional (NJ) CLDN1 expressed on certain tumor cells.
This prevents CLDN1-mediated signaling, which disrupts the stiff extracellular matrix
(ECM) in tumors and, by disturbing the physical barrier, enhances the infiltration
of immune cells, such as natural killer cells (NKs) and T-cells. This abrogates immunosuppression
in the tumor microenvironment (TME) and leads to NK- and T-cell-mediated tumor cell
killing. In addition, eclutatug can directly kill CLDN1-expressing tumor cells via
antibody-dependent cell mediated cytotoxicity (ADCC). CLDN1, which is normally confined
within the tight junctions in epithelial tissues, is overexpressed on a variety of
tumor cells in a non-junctional form. CLDN1 overexpression on tumor cells correlates
with ECM remodeling and T-cell exclusion, and is associated with reduced efficacy
of checkpoint inhibitors (CPIs).;
UNII : 78938RG6AM;
CAS number : 2922054-25-7;
Molecule name : ALE-C04; ALE.C04; ALE C04;
NCI Metathesaurus CUI : CL1920659;
Origin ID : C201755;
UMLS CUI : C5907927;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
